Experimental Study on Early Diagnosis of Malignant Pleural Mesothelioma with Computed Tomography Combined Serum Soluble Mesothelin-Related Proteins

被引:0
|
作者
Jiang Jie [1 ]
Qin Zhanxiong [2 ]
Wu Li [1 ]
Xie Xiaojie [1 ]
Zhao Xunran [1 ]
Zhao Wen [1 ]
Han Dan [1 ]
机构
[1] Kunming Med Univ, Affiliated Hosp 1, Dept Med Imaging, Kunming 650032, Yunnan, Peoples R China
[2] Kunming City Maternal & Child Hlth Hosp, Radiol Dept, Kunming 650031, Yunnan, Peoples R China
基金
中国国家自然科学基金;
关键词
Computed Tomography; Mesothelium; Malignant Pleural Mesothelioma; Serum Soluble Mesothelin-Related Proteins; PROGNOSTIC VALUE; PEPTIDES;
D O I
10.1166/jmihi.2021.3314
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Objective: To investigate the value on early diagnosis of experimental rat according to computed tomography (CT) combined with the serum level of Serum Soluble Mesothelin-related Proteins (SMRP). Methods: Thirty-two SD rat were divided into three groups, including group A (experimental group) of 20 rats with pleural cavity injection of crocidolite suspension, group B (negative control group) of 6 rats with pleural cavity injection of saline, group C (blank control group) of 6 rats without any processing. Chest and abdominal CT scan and enhancement were performed in the three months and six months after induction and the pleural thickening was analyzed. The serum level of SMRP was measured at the different time period including pre-injection, the post-injection first month, the second month, the third month and the sixth month. The correlation between pleural thickening and serum level of SMRP was analyzed. Results: In group A: 20 cases were performed on CT scan in post-injection third month and we found 13 cases without pleural lesions and 7 cases with pleural lesions including of 4 cases with mild pleural thickening, 1 moderate thickening and 2 severe thickening (2 cases died). Moreover, 18 cases were done by CT in post-injection third month and we found 3 cases without pleural lesions and 15 cases with pleural lesions including of 6 cases with mild pleural thickening, 5 moderate thickening and 4 severe thickening (3 cases died). No pleural lesions were found in group B and group C. SMRP expression level differences in the three groups was statistically significant. However, there was no difference in pre-injection in the three groups and there were no difference in group B and C at the different time period. In group A, there was no difference between post-injection first month and second month, whereas, there had statistically difference in post-injection third and sixth month. In group A, SMRP level gradually increased over time. The high correlation between pleural thickening and serum level of SMRP was seen at the post-injection third and sixth month, which the expression of SMRP gradually increased as the pleural thickening. Conclusion: Serum SMRP expression level has a certain value for early diagnosis and staging of MPM, which can be used as an important biomarker for early screening of high-risk groups exposed to asbestos.
引用
收藏
页码:667 / 671
页数:5
相关论文
共 50 条
  • [31] Detection of Soluble Mesothelin in Serum and Pleural Effusion of Malignant Pleural Mesothelioma: A Contribution to Cytology
    Fedeli, F.
    Canessa, P. A.
    Ferro, P.
    Battolla, E.
    Dessanti, P.
    Vigani, A.
    Chiaffi, L.
    Franceschini, M. C.
    Fontana, V.
    Bacigalupo, B.
    Pistillo, M. P.
    Roncella, S.
    MODERN PATHOLOGY, 2013, 26 : 452A - 452A
  • [32] Combined Serum Mesothelin and Plasma Osteopontin Measurements in Malignant Pleural Mesothelioma
    Cristaudo, Alfonso
    Bonotti, Alessandra
    Simonini, Silvia
    Vivaldi, Agnese
    Guglielmi, Giovanni
    Ambrosino, Nicolino
    Chella, Antonio
    Lucchi, Marco
    Mussi, Alfredo
    Foddis, Rudy
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (09) : 1587 - 1593
  • [33] Clinical evaluation of soluble mesothelin-related peptide (Mesomark) in mesothelioma, benign and malignant lung diseases
    Stieber, Petra
    Hatz, Rudolph
    Holdenrieder, Stefan
    Reinmiedl, Judith
    Hofmann, Karin
    Schalhorn, Andreas
    TUMOR BIOLOGY, 2006, 27 : 41 - 41
  • [34] Diagnostic and prognostic value of soluble mesothelin related proteins (SMRP) in sera of patients with malignant pleural mesothelioma
    Muley, Thomas
    Traschuetz, Christa
    Meister, Michael
    Hoffmann, Hans
    Dienemann, Hendrik
    Herth, Felix J. F.
    Philipp, Monika
    Schneider, Joachim
    TUMOR BIOLOGY, 2007, 28 : 101 - 101
  • [35] Association of miR-126 with soluble mesothelin-related peptides: a novel marker for malignant mesothelioma
    Sartini, D.
    Santarelli, L.
    Strafella, E.
    Staffolani, S.
    Amati, M.
    Morganti, S.
    Pozzi, V.
    Carbonari, D.
    Bracci, M.
    Pignotti, E.
    Mazzanti, P.
    Sabbatini, A.
    Ranaldi, R.
    Gasparini, S.
    Neuzil, J.
    Tomasetti, M.
    Emanuelli, M.
    FEBS JOURNAL, 2011, 278 : 232 - 232
  • [36] Soluble mesothelin related peptides: A potential biomarker for malignant pleural mesothelioma.
    Pass, HI
    Wolaniuk, D
    Wali, A
    Thiel, R
    Hellstrom, I
    Hellstrom, K
    Sardesai, NY
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 844S - 844S
  • [37] Commentator Discussion: Soluble mesothelin-related peptide as a prognosticator in pleural mesothelioma patients receiving checkpoint immunotherapy
    Mitra, Sonali
    Adusumilli, Prasad
    Lee, Hyun-Sung
    Burt, Bryan M.
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2025, 169 (04): : 1096 - 1097
  • [38] Is Soluble Mesothelin-Related Protein an Upfront Predictive Marker of Pleural Mesothelioma? A Prospective Study on Italian Workers Exposed to Asbestos
    Filiberti, Rosa
    Marroni, Paola
    Spigno, Fabio
    Merlo, Domenico F.
    Mortara, Virginia
    Caruso, Pietro
    Cioe, Alex
    Michelazzi, Luigi
    Bruzzone, Andrea
    Bobbio, Barbara
    Simonassi, Claudio
    Del Corso, Lisette
    Galli, Roberto
    Racchi, Omar
    Dini, Guglielmo
    Linares, Roberta
    Mencoboni, Manlio
    ONCOLOGY, 2014, 86 (01) : 33 - 43
  • [39] Improved diagnosis of mesothelioma by a combination of soluble mesothelin-related peptide and CYFRA 21-1
    Holdenrieder, Stefan
    Hatz, Rudolf
    Reinmiedl, Judith
    Hofmann, Karin
    Schalhorn, Andreas
    Stieber, Petra
    LABORATORIUMSMEDIZIN-JOURNAL OF LABORATORY MEDICINE, 2015, 39 (02): : 103 - 113
  • [40] Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment
    Grigoriu, Bogdan-Dragos
    Scherpereel, Arnaud
    Devos, Patrick
    Chahine, Bachar
    Letourneux, Marc
    Lebailly, Pierre
    Gregoire, Marc
    Porte, Henri
    Copin, Marie-Christine
    Lassalle, Philippe
    CLINICAL CANCER RESEARCH, 2007, 13 (10) : 2928 - 2935